Abstract BACKGROUND Brain Metastases (BM) occur in the natural course of malignant tumors and cause a high rate of morbidity and mortality. The approaches to their management have changed considerably over the past decade. We aimed to give an update regarding the current means of diagnosis, management, and the outcomes of brain metastases in LMIC. METHODS We searched PubMed, ScienceDirect, Medline, Embase, Global Index Medicus, African Journals Online, and Google Scholar for studies reporting data on Brain metastasis diagnosis, management, and outcomes in LMICs from inception to October 23rd, 2022. The systematic review was conducted using the PRISMA principles. RESULTS A total of 7916 unique studies were identified, of which, 48 were included. The most studied (21, 43.75%) and common cause of metastases was lung tumors (1602, 51.43%). A subtotal resection (STR) was archived in the majority of reported cases in the frequency of 56.2% (n = 1751), gross total resection (GTR) in 37.5% (n = 1169) of cases, while only biopsy was possible in 6.3% (n = 195). The reported adjuvant treatments were radiotherapy 39.9% (n = 1036), radiosurgery 22.5% (n = 585), and radiosurgery + radiotherapy 37.5% (N = 974). Management of the primary tumor was reported in 13 (27.08%) studies. Half (24, 50%) of the studies reported the overall survival time to be 4-52 months. CONCLUSION Lung, breast, and GI tumors were the most common primary tumors for the MB. Whole-brain radiotherapy is the most common management method in LMICs.